Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer

Vignoli, Alessia; Risi, Emanuela; McCartney, Amelia; Migliaccio, Ilenia; Moretti, Erica; Malorni, Luca; Luchinat, Claudio; Biganzoli, Laura; Tenori, Leonardo

doi:10.3390/ijms22094687

Cited by 28 publications

(28 citation statements)

References 140 publications

(182 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer is a major global health problem issue, which exacts a heavy toll on healthcare systems [46] . Metabolomics defines a post-genomic research field, embracing small molecule analysis applied to utilizing biomarkers for cancer detection, monitoring, and prognostication [47] . Emerging discoveries of metabolomics promise to provide a suitable alternative for the current cancer diagnostic methods, notably including standard histopathological analysis [47] .…”

Section: Cancermentioning

confidence: 99%

“…Metabolomics defines a post-genomic research field, embracing small molecule analysis applied to utilizing biomarkers for cancer detection, monitoring, and prognostication [47] . Emerging discoveries of metabolomics promise to provide a suitable alternative for the current cancer diagnostic methods, notably including standard histopathological analysis [47] . Interestingly, formalin-fixed paraffin-embedded tissue specimens, which are commonly obtained for histopathological evaluation, are a valuable source for metabolomics investigations and can provide additional informative data for assessing disease stage and individual treatment responses.…”

Section: Cancermentioning

confidence: 99%

“…Interestingly, formalin-fixed paraffin-embedded tissue specimens, which are commonly obtained for histopathological evaluation, are a valuable source for metabolomics investigations and can provide additional informative data for assessing disease stage and individual treatment responses. However, there remain some limitations to be addressed to optimize their utilization for metabolomics analysis [47] .…”

Section: Cancermentioning

confidence: 99%

See 2 more Smart Citations

Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

Lonardo¹,

Byrne²,

Targher³

2021

MTOD

View full text Add to dashboard Cite

In this review, we discuss selected topics which are relevant to implementing precision medicine in metabolic disorders. Personalization of diet and exercise may help in preventing obesity and type 2 diabetes (T2D). Weight loss should be personalized based on age, sex, ethnicity, and coexisting comorbidities. Advances in our understanding of the pathophysiology, genetics, and epigenetics of obesity promise to offer tailored management options. Careful risk assessment is necessary prior to intervention. Risk may be underestimated, e.g., in women, in different ethnic groups, and in people with T2D. More personalized approaches could be useful among persons who failed to respond to traditional risk factor management, such as pharmacological treatment for dyslipidemia and arterial hypertension. Nonalcoholic fatty liver disease/metabolic-associated fatty liver disease (NAFLD/MAFLD) is both a cause and an effect of altered glucose and lipid metabolism. Personalized medicine approaches could be key to identify more effective pharmacological strategies as well as to reverse this common and burdensome metabolic liver disease. Finally, metabolomics could be used to identify relevant biomarkers for cancer diagnosis, staging, and prognostication. Cancers of the colon and rectum, breast, prostate, thyroid, and ovaries illustrate the notion that cancer cell metabolic derangements may be utilized in clinical practice. A true personalization of pharmacotherapies should be pursued especially in obese patients with cancer.

show abstract

Section: Cancermentioning

confidence: 99%

Section: Cancermentioning

confidence: 99%

Section: Cancermentioning

confidence: 99%

See 1 more Smart Citation

Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

Lonardo¹,

Byrne²,

Targher³

2021

MTOD

View full text Add to dashboard Cite

show abstract

“…In this regard, the concept of a precision medicine model where a group of breast cancer patients are selected based on a metastasis-related molecule which is subsequently, targeted (as elaborated in Section 5), seems to be an attractive therapeutic strategy. Precision medicine is an emerging approach for breast cancer therapy with the aim of selecting the optimal therapy for a specific group of cancer patients [18].…”

Section: Introductionmentioning

confidence: 99%

Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer

Viera

Yip

Shen

et al. 2021

Cancers

View full text Add to dashboard Cite

Metastasis is the main cause of mortality in breast cancer patients. There is an unmet need to develop therapies that can impede metastatic spread. Precision oncology has shown great promise for the treatment of cancers, as the therapeutic approach is tailored to a specific group of patients who are likely to benefit from the treatment, rather than the traditional approach of “one size fits all”. CD82, also known as KAI1, a glycoprotein belonging to the tetraspanin family and an established metastasis suppressor, could potentially be exploited to hinder metastases in breast cancer. This review explores the prospect of targeting CD82 as an innovative therapeutic approach in precision medicine for breast cancer patients, with the goal of preventing cancer progression and metastasis. Such an approach would entail the selection of a subset of breast cancer patients with low levels of CD82, and instituting an appropriate treatment scheme tailored towards restoring the levels of CD82 in this group of patients. Proposed precision treatment regimens include current modalities of treating breast cancer, in combination with either clinically approved drugs that could restore the levels of CD82, CD82 peptide mimics or non-coding RNA-based therapeutics.

show abstract

“…Cancer heterogeneity presents major challenges for the development of personalized treatments [ 1 , 2 , 3 , 4 ]. Current precision therapies used in the treatment of cancer are designed to exploit a variety of different biological entities characteristic to individual cancer types, such as activated protein kinases, estrogen receptor, and defective DNA repair enzymes [ 4 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Functional Roles of Bromodomain Proteins in Cancer

Boyson

Gao

Quinn

et al. 2021

Cancers

View full text Add to dashboard Cite

Histone acetylation is generally associated with an open chromatin configuration that facilitates many cellular processes including gene transcription, DNA repair, and DNA replication. Aberrant levels of histone lysine acetylation are associated with the development of cancer. Bromodomains represent a family of structurally well-characterized effector domains that recognize acetylated lysines in chromatin. As part of their fundamental reader activity, bromodomain-containing proteins play versatile roles in epigenetic regulation, and additional functional modules are often present in the same protein, or through the assembly of larger enzymatic complexes. Dysregulated gene expression, chromosomal translocations, and/or mutations in bromodomain-containing proteins have been correlated with poor patient outcomes in cancer. Thus, bromodomains have emerged as a highly tractable class of epigenetic targets due to their well-defined structural domains, and the increasing ease of designing or screening for molecules that modulate the reading process. Recent developments in pharmacological agents that target specific bromodomains has helped to understand the diverse mechanisms that bromodomains play with their interaction partners in a variety of chromatin processes, and provide the promise of applying bromodomain inhibitors into the clinical field of cancer treatment. In this review, we explore the expression and protein interactome profiles of bromodomain-containing proteins and discuss them in terms of functional groups. Furthermore, we highlight our current understanding of the roles of bromodomain-containing proteins in cancer, as well as emerging strategies to specifically target bromodomains, including combination therapies using bromodomain inhibitors alongside traditional therapeutic approaches designed to re-program tumorigenesis and metastasis.

show abstract

Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer

Cited by 28 publications

References 140 publications

Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer

Functional Roles of Bromodomain Proteins in Cancer

Contact Info

Product

Resources

About